A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression

被引:31
作者
Iruzubieta, Paula [1 ]
Medina, Juan M. [2 ]
Fernandez-Lopez, Raul [2 ]
Crespo, Javier [1 ]
de la Cruz, Fernando [2 ]
机构
[1] Marques Valdecilla Univ Hosp, Gastroenterol & Hepatol Dept, Clin & Translat Digest Res Grp, IDIVAL, Santander 39008, Spain
[2] Univ Cantabria, Inst Biomed & Biotecnol Cantabria IBBTEC, Santander 39011, Spain
关键词
NAFLD; gut microbiome; microbial metabolic pathway; microbiome-based signature; fecal microbiota transplantation; TRIMETHYLAMINE N-OXIDE; ETHANOL-INDUCED DISRUPTION; ACTIVE ULCERATIVE-COLITIS; PROTEIN-COUPLED RECEPTOR; NONALCOHOLIC STEATOHEPATITIS; BARRIER DYSFUNCTION; UP-REGULATION; HOST; OBESE; ACID;
D O I
10.3390/jcm9051369
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease in which environmental and genetic factors are involved. Although the molecular mechanisms involved in NAFLD onset and progression are not completely understood, the gut microbiome (GM) is thought to play a key role in the process, influencing multiple physiological functions. GM alterations in diversity and composition directly impact disease states with an inflammatory course, such as non-alcoholic steatohepatitis (NASH). However, how the GM influences liver disease susceptibility is largely unknown. Similarly, the impact of strategies targeting the GM for the treatment of NASH remains to be evaluated. This review provides a broad insight into the role of gut microbiota in NASH pathogenesis, as a diagnostic tool, and as a therapeutic target in this liver disease. We highlight the idea that the balance in metabolic fermentations can be key in maintaining liver homeostasis. We propose that an overabundance of alcohol-fermentation pathways in the GM may outcompete healthier, acid-producing members of the microbiota. In this way, GM ecology may precipitate a self-sustaining vicious cycle, boosting liver disease progression.
引用
收藏
页数:17
相关论文
共 50 条
  • [31] The role of the gut microbiome in chronic liver disease: the clinical evidence revised
    Schwenger, Katherine J. P.
    Clermont-Dejean, Nayima
    Allard, Johane P.
    JHEP REPORTS, 2019, 1 (03) : 214 - 226
  • [32] Deciphering the role of gut metabolites in non-alcoholic fatty liver disease
    Ralli, Tanya
    Saifi, Zoya
    Tyagi, Neha
    Vidyadhari, Arya
    Aeri, Vidhu
    Kohli, Kanchan
    CRITICAL REVIEWS IN MICROBIOLOGY, 2023, 49 (06) : 815 - 833
  • [33] The Role of Dietary Fiber and Gut Microbiome Modulation in Progression of Chronic Kidney Disease
    Ranganathan, Natarajan
    Anteyi, Emmanuel
    TOXINS, 2022, 14 (03)
  • [34] Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact
    Alisi, Anna
    Mccaughan, Geoffrey
    Gronbaek, Henning
    HEPATOLOGY INTERNATIONAL, 2024, 18 (SUPPL 2) : 861 - 872
  • [35] The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease
    Kanellos, Panagiotis T.
    Baxevanis, Georgios K.
    Tentolouris, Anastasios
    Gavriatopoulou, Maria
    Ntanasis-Stathopoulos, Ioannis
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [36] The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC
    Song, Qian
    Zhang, Xiang
    BIOMEDICINES, 2022, 10 (03)
  • [37] Gut Microbiome Signatures in the Progression of Hepatitis B Virus-Induced Liver Disease
    Li, Ranxi
    Yi, Xinzhu
    Yang, Junhao
    Zhu, Zhou
    Wang, Yifei
    Liu, Xiaomin
    Huang, Xili
    Wan, Yu
    Fu, Xihua
    Shu, Wensheng
    Zhang, Wenjie
    Wang, Zhang
    FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [38] Gut microbiome composition and metabolic activity in metabolic-associated fatty liver disease
    Zhang, Daya
    Wang, Qi
    Li, Da
    Chen, Shiju
    Chen, Jinrun
    Zhu, Xuli
    Bai, Feihu
    VIRULENCE, 2025, 16 (01)
  • [39] Understanding the role of ursodeoxycholic acid and gut microbiome in non-alcoholic fatty liver disease: current evidence and perspectives
    Mao, Qingyi
    Lin, Beibei
    Zhang, Wenluo
    Zhang, Yu
    Zhang, Yu
    Cao, Qian
    Xu, Mengque
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [40] Pregnane X receptor exacerbates nonalcoholic fatty liver disease accompanied by obesity- and inflammation-prone gut microbiome signature
    Kim, Sarah
    Choi, Sora
    Dutta, Moumita
    Asubonteng, Jeffrey O.
    Polunas, Marianne
    Goedken, Michael
    Gonzalez, Frank J.
    Cui, Julia Yue
    Gyamfi, Maxwell A.
    BIOCHEMICAL PHARMACOLOGY, 2021, 193